Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial-Reference-Cited by-同舟云学术

Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial

Published:2016-04-02 Issue:1 Volume:13 Page:
ISSN:1742-6405
Container-title:AIDS Research and Therapy
language:en
Short-container-title:AIDS Res Ther

Author:

de Castro Nathalie, ,Braun Joséphine,Charreau Isabelle,Lafeuillade Alain,Viard Jean-Paul,Allavena Clotilde,Aboulker Jean-Pierre,Molina Jean-Michel

Funder

Agence Nationale de Recherches sur le Sida et les Hepatites Virales

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Virology,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12981-016-0101-3

Reference15 articles.

1. Núñez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology. 2010;52:1143–55.

2. Soriano V, Puoti M, Garcia-Gascó P, Rockstroh JK, Benhamou Y, Barreiro P, McGovern B. Antiretroviral drugs and liver injury. AIDS. 2008;22:1–13.

3. Vispo E, Fernández-Montero JV, Labarga P, Barreiro P, Soriano V. Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients. AIDS. 2013;27:1187–8.

4. Teppler H, Brown DD, Leavitt RY, Sklar P, Wan H, Xu X, et al. Long-term safety from the raltegravir clinical development program. Curr HIV Res. 2011;9:40–53.

5. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H, BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339–54.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Alzheimer’s Disease-Associated Aβ Therapy Based on Peptide;International Journal of Molecular Sciences;2023-08-23

2. Current status and trends in research and development of polypeptide drugs;Privileged Scaffolds in Drug Discovery;2023

3. Artificial intelligence channelizing protein-peptide interactions pipeline for host-parasite paradigm in IL-10 and IL-12 reciprocity by SHP-1;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2022-10

4. Therapeutic peptides: current applications and future directions;Signal Transduction and Targeted Therapy;2022-02-14

5. Incidence of Hepatotoxicity and Factors Associated During Highly Active Antiretroviral Therapy in People Living with HIV in Ethiopia: A Prospective Cohort Study;HIV/AIDS - Research and Palliative Care;2021-03